NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
09 June 2025
| Name: | ANAGENICS LIMITED (AN1) | |||||||||
| ISIN: | AU0000198095 | |||||||||
| Date of Listing: | 09 December 2005 | |||||||||
| Former Names: |
|
Stock Exchange Status: (updated daily)
This entity is currently listed and quoted on the Australian Securities Exchange.Legal Status: (updated monthly)
ACN: 111 304 119ABN: 69 111 304 119
Registration Date: 08 October 2004
Capital Gains Tax (CGT) Status: (updated at least quarterly)
To crystallise a capital gain or capital loss on your securities in this entity, you are able to sell your securities on-market in the normal manner. If you determine that the market in your securities is illiquid and you still wish to crystallise a capital gain or loss, kindly contact deListed at admin@delisted.com.au for suggestions as to how you might proceed.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| FROM | TO | |
| ANAGENICS LIMITED | 15/12/2021 | |
| CELLMID LIMITED | 20/11/2009 | 15/12/2021 |
| MEDICAL THERAPIES LIMITED | 20/11/2009 |
Automic Group
Level 5, 126 Philip Street Sydney NSW 2000
GPO Box 5193 Sydney NSW 2001
Tel : 1300 288 664 or +61 2 9698 5414
Fax : +61 2 8583 3040
RegistryWebsite RegistryEmail
Expand this box to read and print
The suspension of trading in the securities of Anagenics Limited is expected to be lifted from the commencement of trading on 5 May 2025 following the release by AN1 of an announcement regarding its financial condition. | 02/05/2025 |
The company releases its appendix 4G and corporate governance statement for June 2024 and also its pre-reinstatement disclosure. | 02/05/2025 |
The company releases its activity report for 2025. | 02/05/2025 |
The company releases its appendix 4C. | 01/05/2025 |
Entities that have been suspended for more than three months due to their unfiled periodic reports, along with the oldest overdue report deadline and their two-year deadline for trading plans, will be removed from the official list if these conditions are not fulfilled. | 09/04/2025 |
The company releases its notice of cessation of securities. | 08/04/2025 |
The company lodges its application for quotation of securities. | 08/04/2025 |
The company's shareholders approved the issue of 35,000,000 AN1 shares to FOS Capital, with an issue price of 1c per share. | 03/04/2025 |
The company releases its results of its general meeting. | 03/04/2025 |
The company reported a net loss of $0.5m for the half-year ended 31 December 2024, a significant improvement from the previous year. The business restructure improved net operating cash flow, with an outflow of $0.3m in 2Q25. The company completed a transition to in-house solutions and new ERP systems, resulting in growth in sales. | 28/02/2025 |
The company will hold its general meeting on 3 April 2025, 10:00am (Sydney time) at Suite 204, Level 2, 55 Clarence Street Sydney NSW 2000. | 27/02/2025 |
The company releases its appendix 4D and half year report. | 27/02/2025 |
The company reported a total payment of $65k to related parties and associates for the 2Q25 Qtrly Activity Report, including wages, fees, and GST paid to former directors. | 10/02/2025 |
The company reports Roquefort Therapeutics has signed a binding share purchase agreement for the sale of Lyramid to Pleiades Pharma, following a previous term sheet with Pleiades. | 04/02/2025 |
The company lodges its Activity Statement and Appendix 4C. | 31/01/2025 |
The entities suspended for over three months failed periodic reports, the oldest outstanding report deadline, and their 2 year deadline for trading plans. If not met, they will be removed from the official list, usually after the first trading day. | 22/01/2025 |
The company receives additional information from the ASX for relisting its securities, including lodgement of quarterly activities report, audit reviewed financial position, sufficient operations, and issuing shares. | 10/01/2025 |
The company has received an update on Roquefort Therapeutics' announcement of a proposed sale of its midkine portfolio, including royalties from products using its intellectual property. The company is making further inquiries and is pursuing discussions with the ASX to end the suspension in trading. | 03/01/2025 |
The company has completed its restructuring program, aiming to return the company to profitability. The restructure includes in-housing third-party logistics and exiting the Chinese online sales channel. Total cost reductions are expected to exceed $2.5 million annually. Anagenics now has a clear strategy focused on profitability, strengthening royalty revenue streams, new brand releases, and pursuing accretive acquisitions. | 02/12/2024 |
The company releases the results of its annual general meeting. | 27/11/2024 |
The company lodges its 2024 AGM Presentation. | 26/11/2024 |
The company lodges its Q1 F25 Activity Statement and Appendix 4C. | 31/10/2024 |
The company is undergoing a restructuring program to reposition itself with a simplified business model, aiming for modest profitability. The company has disposed of a loss-making business and reduced liabilities. The restructuring includes reducing head count, replacing IT and ERP systems, and reducing overhead costs. | 31/10/2024 |
The company 2024 Annual General Meeting is scheduled for November 26, 2024, at Level 2, 55 Clarence Street Sydney NSW 2000, at 9.00 am (AEDT). | 21/10/2024 |
The company has completed the sale of Face MediGroup, as previously announced on October 2, 2024. | 16/10/2024 |
The company will release 13,157,895 fully paid ordinary shares from escrow on 11 October 2024, following a 12-month voluntary escrow period, as per ASX Listing Rule 3.10A. | 11/10/2024 |
The company's Board announces a restructuring update, focusing on business simplification and cost reduction. The company's exit from Face MediGroup and the removal of legacy expenses are part of a plan to achieve modest profitability. | 08/10/2024 |
The company releases its Appendix 4G and Corporate Governance Statement. | 04/10/2024 |
The Company has entered into an agreement for the sale of its Face MediGroup business to the co-founders of the business, Matthew Perry and Sarah Jane Perry, and their entities controlled by them. The transaction will see the Company fully exit the FMG business, with the purchasers taking on all assets, liabilities and business specific employees with their accrued entitlements, allowing the Company to reduce its operating costs and avoid significant further costs. The consideration comprises the assumption of FMG's liabilities and cancellation of the Company's obligation to pay approximately $670,000 to the co-founders by way of deferred consideration and loan repayment, supported by mutual releases given by each party. No cash consideration will be exchanged on settlement of this transaction. Completion of the transaction is expected to occur on 15 October 2024. | 02/10/2024 |
The company lodges its Annual Report to shareholders. | 01/10/2024 |
The Company is actively engaged with a number of third parties in relation to multiple restructuring workstreams for the business, including management and funding strategies for the ongoing business. Successful completion of the Restructuring is critical to the Company's continued financial sustainability. Discussions with third parties are progressing positively and constructively. In the Company's opinion, trading of its securities during this time is likely to materially prejudice its ability to complete the discussions with third parties. The Company's suspension will remain in place until the Company releases a further announcement regarding the Restructuring. Discussions are ongoing and it is difficult to predict a timetable for their conclusion. However, the Company is working towards finalising these matters as soon as practicable and is aiming to do so by Monday, 30 September 2024. | 10/09/2024 |
The securities of Anagenics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of AN1, pending the release of an announcement regarding its proposed restructure and financing to fund the ongoing operations which are critical to its continued financial viability. | 04/09/2024 |
name changed from Cellmid Limited | 15/12/2021 |
The suspension of trading in the securities of Anagenics Limited is expected to be lifted from the commencement of trading on 5 May 2025 following the release by AN1 of an announcement regarding its financial condition. | 02/05/2025 |
The company releases its appendix 4G and corporate governance statement for June 2024 and also its pre-reinstatement disclosure. | 02/05/2025 |
The company releases its activity report for 2025. | 02/05/2025 |
The company releases its appendix 4C. | 01/05/2025 |
Entities that have been suspended for more than three months due to their unfiled periodic reports, along with the oldest overdue report deadline and their two-year deadline for trading plans, will be removed from the official list if these conditions are not fulfilled. | 09/04/2025 |
The company releases its notice of cessation of securities. | 08/04/2025 |
The company lodges its application for quotation of securities. | 08/04/2025 |
The company's shareholders approved the issue of 35,000,000 AN1 shares to FOS Capital, with an issue price of 1c per share. | 03/04/2025 |
The company releases its results of its general meeting. | 03/04/2025 |
The company reported a net loss of $0.5m for the half-year ended 31 December 2024, a significant improvement from the previous year. The business restructure improved net operating cash flow, with an outflow of $0.3m in 2Q25. The company completed a transition to in-house solutions and new ERP systems, resulting in growth in sales. | 28/02/2025 |
The company will hold its general meeting on 3 April 2025, 10:00am (Sydney time) at Suite 204, Level 2, 55 Clarence Street Sydney NSW 2000. | 27/02/2025 |
The company releases its appendix 4D and half year report. | 27/02/2025 |
The company reported a total payment of $65k to related parties and associates for the 2Q25 Qtrly Activity Report, including wages, fees, and GST paid to former directors. | 10/02/2025 |
The company reports Roquefort Therapeutics has signed a binding share purchase agreement for the sale of Lyramid to Pleiades Pharma, following a previous term sheet with Pleiades. | 04/02/2025 |
The company lodges its Activity Statement and Appendix 4C. | 31/01/2025 |
The entities suspended for over three months failed periodic reports, the oldest outstanding report deadline, and their 2 year deadline for trading plans. If not met, they will be removed from the official list, usually after the first trading day. | 22/01/2025 |
The company receives additional information from the ASX for relisting its securities, including lodgement of quarterly activities report, audit reviewed financial position, sufficient operations, and issuing shares. | 10/01/2025 |
The company has received an update on Roquefort Therapeutics' announcement of a proposed sale of its midkine portfolio, including royalties from products using its intellectual property. The company is making further inquiries and is pursuing discussions with the ASX to end the suspension in trading. | 03/01/2025 |
The company has completed its restructuring program, aiming to return the company to profitability. The restructure includes in-housing third-party logistics and exiting the Chinese online sales channel. Total cost reductions are expected to exceed $2.5 million annually. Anagenics now has a clear strategy focused on profitability, strengthening royalty revenue streams, new brand releases, and pursuing accretive acquisitions. | 02/12/2024 |
The company releases the results of its annual general meeting. | 27/11/2024 |
The company lodges its 2024 AGM Presentation. | 26/11/2024 |
The company lodges its Q1 F25 Activity Statement and Appendix 4C. | 31/10/2024 |
The company is undergoing a restructuring program to reposition itself with a simplified business model, aiming for modest profitability. The company has disposed of a loss-making business and reduced liabilities. The restructuring includes reducing head count, replacing IT and ERP systems, and reducing overhead costs. | 31/10/2024 |
The company 2024 Annual General Meeting is scheduled for November 26, 2024, at Level 2, 55 Clarence Street Sydney NSW 2000, at 9.00 am (AEDT). | 21/10/2024 |
The company has completed the sale of Face MediGroup, as previously announced on October 2, 2024. | 16/10/2024 |
The company will release 13,157,895 fully paid ordinary shares from escrow on 11 October 2024, following a 12-month voluntary escrow period, as per ASX Listing Rule 3.10A. | 11/10/2024 |
The company's Board announces a restructuring update, focusing on business simplification and cost reduction. The company's exit from Face MediGroup and the removal of legacy expenses are part of a plan to achieve modest profitability. | 08/10/2024 |
The company releases its Appendix 4G and Corporate Governance Statement. | 04/10/2024 |
The Company has entered into an agreement for the sale of its Face MediGroup business to the co-founders of the business, Matthew Perry and Sarah Jane Perry, and their entities controlled by them. The transaction will see the Company fully exit the FMG business, with the purchasers taking on all assets, liabilities and business specific employees with their accrued entitlements, allowing the Company to reduce its operating costs and avoid significant further costs. The consideration comprises the assumption of FMG's liabilities and cancellation of the Company's obligation to pay approximately $670,000 to the co-founders by way of deferred consideration and loan repayment, supported by mutual releases given by each party. No cash consideration will be exchanged on settlement of this transaction. Completion of the transaction is expected to occur on 15 October 2024. | 02/10/2024 |
The company lodges its Annual Report to shareholders. | 01/10/2024 |
The Company is actively engaged with a number of third parties in relation to multiple restructuring workstreams for the business, including management and funding strategies for the ongoing business. Successful completion of the Restructuring is critical to the Company's continued financial sustainability. Discussions with third parties are progressing positively and constructively. In the Company's opinion, trading of its securities during this time is likely to materially prejudice its ability to complete the discussions with third parties. The Company's suspension will remain in place until the Company releases a further announcement regarding the Restructuring. Discussions are ongoing and it is difficult to predict a timetable for their conclusion. However, the Company is working towards finalising these matters as soon as practicable and is aiming to do so by Monday, 30 September 2024. | 10/09/2024 |
The securities of Anagenics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of AN1, pending the release of an announcement regarding its proposed restructure and financing to fund the ongoing operations which are critical to its continued financial viability. | 04/09/2024 |
name changed from Cellmid Limited | 15/12/2021 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 16/05/2025 | Alexander Beard | 55,564 | $0.006 | $336 |
| 14/05/2025 | Alexander Beard | 226,881 | $0.006 | $1,373 |
| 08/05/2025 | Alexander Beard | 2,963,488 | $0.007 | $21,965 |
| 05/05/2025 | Alexander Beard | 1,734,067 | $0.008 | $12,924 |
| 11/03/2024 | Alexander Beard | 66,133 | $0.015 | $992 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Alexander Beard | Non Exec Chairman | 15/02/2022 |
| Dominic Burg | COO | 01/07/2020 |
| Matthew Dudek | CFO | 28/02/2022 |
| Phillip Christopher | Non Exec Director | 05/11/2021 |
| Scott Greasley | Executive Director | 08/07/2022 |
| Hemant Amin | Company Secretary | 13/06/2024 |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Karen Matthews | Director, CEO | 14/02/2024 | 31/10/2024 |
| Martin Cross | Non Exec Director | 16/10/2017 | 27/11/2023 |
| Dennis Eck | Non Exec Director | 26/03/2018 | 29/11/2022 |
| Maria Halasz | Managing Director, CEO | 16/04/2007 | 28/02/2022 |
| Lee Tamplin | Company Secretary | 28/02/2022 | |
| Bruce Gordon | Chairman, Independent Director | 01/07/2015 | 15/02/2022 |
| Sarah Eck-Thompson | Alternate Director | 21/10/2020 | 04/11/2021 |
| David King | Non Exec Chairman | 18/01/2008 | 31/12/2020 |
| Fintan Walton | Non Exec Director | 21/07/2015 | 30/11/2020 |
| Martin Rogers | Non Exec Director | 19/09/2012 | 30/06/2015 |
| Graeme Kaufman | Non Exec Director | 27/08/2012 | 30/06/2015 |
| Robin Beaumont | Non Exec Director | 12/10/2009 | 27/08/2012 |
| Koichiro Koike | Director | 09/12/2010 | |
| Stephanie Williams | Executive Director | 15/02/2008 | 26/08/2008 |
| Michael Taverner | Non Exec Director | 08/10/2004 | 15/02/2008 |
| Michael Vitale | Chairman | 16/12/2004 | 18/01/2008 |
| Malcom Castle | Non Exec Director | 23/02/2006 | 21/05/2007 |
| Llewellyn Casbolt | Managing Director | 16/12/2004 | 15/11/2006 |
| James Dominguez | Chairman | 16/12/2004 | 09/03/2006 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.